Scott Paulson, MD
The treatment landscape of neuroendocrine tumors (NETs) has experienced exponential growth with the addition of several new agents after decades of limited therapeutic options. Now, clinicians must focus on how to optimally sequence these therapies, said Scott Paulson, MD.
One of the most recent updates in this landscape was in January 2018 with the FDA approval of Lutathera (lutetium Lu 177 dotatate) for the treatment of patients with somatostatin receptor–positive gastroenteropancreatic NETs. Results from the phase III NETTER-1 trial, which compared Lutathera with high-dose octreotide LAR for patients with grade 1 or 2 metastatic midgut NETs, led to this approval. These findings showed a 79% reduction in the risk of progression or death with Lutathera compared with octreotide.
... to read the full story